Johanna Friedl-Naderer - Sep 3, 2024 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Role
Chief Commercial Officer
Signature
/s/ Richard Scalzo, Attorney-in-Fact
Stock symbol
DYN
Transactions as of
Sep 3, 2024
Transactions value $
$0
Form type
4
Date filed
9/3/2024, 06:16 PM
Previous filing
Mar 7, 2023
Next filing
Dec 6, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DYN Common Stock Award $0 +58.4K $0.00 58.4K Sep 3, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DYN Stock Option (Right to Buy) Award $0 +185K $0.00 185K Sep 3, 2024 Common Stock 185K $31.94 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of shares of Common Stock issuable under 58,400 restricted stock units ("RSU"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on September 3, 2025.
F2 This option was granted on September 3, 2024. The shares underlying the option are scheduled to vest over four years, with 25% of the shares vesting on September 3, 2025, and the remainder vesting in equal quarterly installments thereafter, subject to continuous service.